Clinical trials for implantable medical devices are transforming cancer care by making therapies more targeted, less toxic, and, eventually, more effective. From drug-eluting stents and intratumoral drug delivery devices to implantable pumps, biodegradable implants, ablation probes, and biosensors, these advancements are transforming cancer care. They are intended to administer therapies exactly where most needed, while minimizing the negative effects of standard systemic treatments.

Gastric cancer is a notable oncology specialty where these devices can have a significant impact. It is often identified at an advanced stage and has few curative therapeutic options. This raises an urgent need for novel techniques to improve patients’ survival rates and quality of life.

In this article, we will address the real-world issues that sponsors face when conducting clinical trials for implantable medical devices, focusing on gastric cancer. These trials are not simple; they involve concerns about how to organize the study, define an appropriate patient population, and select relevant objectives that accurately reflect patient outcomes. Additionally, sponsors must choose where to conduct these studies, weighing areas with superior infrastructure versus those with a high disease burden.

Before delving into the article, let’s first look at the global disease burden in this segment.

Global disease burden of gastric cancer

Gastric cancer remains one of the most common and deadly cancers in the world. According to GLOBOCAN 2022 estimates published in CA: A Cancer Journal for Clinicians, it was responsible for almost 9,68,000 new cases and approximately 6,60,000 deaths, ranking as the fifth most common cancer in both incidence and mortality.

The burden is unevenly distributed. With many patients receiving a late diagnosis and limited access to curative therapies, East Asia, Eastern Europe, and portions of South America bear the brunt of the burden. As a result, 5-year overall survival rates remain below 40% in most countries. 

The significance of careful clinical trial preparation is underscored by these alarming data. High-burden regions provide large patient pools for recruitment. However, sponsors often face challenges with care quality and complex regulations. Low-burden regions, on the other hand, may have more efficient logistics but struggle to enrol enough patients on time. 

Finding the ideal balance between these realities is essential to guaranteeing that trial findings are both practical and applicable around the world.

Current status of clinical trials in gastric cancer

With an increasing focus on implantable medical devices that target treatment directly at the tumour site, the landscape of clinical trials for gastric cancer is evolving quickly. These developments aim to enhance patient outcomes, lessen side effects, and fill in gaps in the current care system. Here are some of the most promising study areas:

• Drug-eluting stents: These stents not only ease tumor-induced obstructions in the stomach or esophagus, but they can also deliver chemotherapy directly to the location. This local method eliminates the requirement for high systemic doses, resulting in fewer side effects.
• Biodegradable implants and intratumoral drug delivery systems: These implants reduce toxicity. They also improve therapy by releasing drugs precisely at the tumor site.
• Implantable pumps/reservoirs: These devices enable the repeated or continuous delivery of medications directly into the tumor or abdominal cavity. This results in improved local concentration and more precise dosing.
• Ablation probes (microwave and radiofrequency): These probes provide a therapy option for people who might not be candidates for surgery by using localized heat to eliminate tumor tissue in a less intrusive manner.
• Devices for cryoablation: Cryoablation uses very low temperatures to freeze and kill malignant tissue. According to preliminary research, combining this with additional local therapies may enhance results even further.

This increasing landscape represents a significant shift in gastric cancer research. These approaches, which focus on localized, patient-centered interventions, are attempting to supplement standard systemic medications. 

Would you like to learn about drug development for a new medical device? Click here.

Clinical trials for gastric cancer globally

Till now, 11 implant-focused gastric cancer trials are registered on ClinicalTrials.gov. These reflect global efforts to improve treatments and outcomes.

Challenges in designing and executing clinical trials for implantable medical devices

It is rarely easy to conduct clinical trials for implantable medical devices. Device trials have a unique set of challenges that sponsors must carefully manage, in contrast to drug-only studies. These difficulties can be roughly divided into five categories:

• Trial design complexity: It arises when inclusion criteria and objectives ignore real-world practice. Such burdens make recruitment more difficult. Protocols may become unworkable and out of step with daily clinical realities if investigators don’t provide early input.
• Defining study populations and endpoints: Gastric cancer is heterogeneous, which makes patient selection difficult. Devices’ full potential may be underrepresented. Localized benefits often do not show up in conventional survival-based outcomes.
• Geographic region selection: Small patient pools, protracted approval processes, or a lack of specialised infrastructure can result from an inappropriate location. Local standards of care, as well as patient acceptance of implanted devices, might have a significant impact on recruitment feasibility.
• Recruitment and retention of patients: Patients may hesitate to enroll in invasive procedures. Long follow-up requirements and complex protocols can raise dropout rates even when patients do join, endangering trial schedules.
• Difficulties in the execution of operations: Even small planning oversights delay trial start-up and progress. Teams must meet legal standards for transporting and storing devices and ensure investigators and sites get proper training.

Optimizing trial design and execution

Overcoming these barriers requires careful planning, early collaboration with investigators, and patient-centered strategies. Real-world methods involve:

• Strengthening trial design: Many gastric cancer device trials fail to recruit because the inclusion criteria are excessively stringent or the endpoints do not accurately reflect the benefit. For instance, a stent trial that solely assessed overall survival did not observe improvements in feeding and comfort. Researchers can avoid this by establishing patient-relevant outcomes and involving investigators early on.
• Smart region selection: Although conducting a trial in East Asia may provide a significant number of patients, sponsors frequently have to deal with lengthy ethics evaluations and rival research. Western Europe, on the other hand, has easier logistics but has trouble with timely enrolment. Therefore, early feasibility checks that balance these trade-offs are critical.
• Patient-centric recruitment & retention: Patients often hesitate to undergo intrusive procedures unless they see tangible benefits. For instance, dropout rates increased in a cryoablation trial due to excessive travel required for frequent follow-ups. By providing telemedicine visits and outlining possible quality-of-life enhancements, involvement can seem valuable.
• Operational efficiency: Logistics-related issues, such as inexperienced personnel at sites or delayed clearances for importing devices, usually cause trials to stall. Proper preparation and training help avoid these setbacks.

Conclusion – Clinical trials for implantable medical devices

Implantable medical device trials represent an evolving frontier in clinical research, offering new possibilities for localized, targeted, and patient-centered treatment. Design, region selection, recruitment, and regulatory processes remain challenging. Careful planning and responsive interventions can greatly improve trial success.

Innovation is crucial in gastric cancer due to high prevalence, delayed diagnosis, and poor outcomes. Insights gained will shape future clinical research across therapeutic areas as implantable device trials advance globally.

---

Are you looking for expert support in conducting clinical trials for implantable medical devices?

Are you facing challenges in planning, designing, or executing clinical trials for implantable medical devices? Share the challenges you are experiencing by filling out the form below, and our expert team will connect with you to provide tailored solutions to help you overcome them.

---